OBJECTIVE: The object of the present study was to identify metabolic differences between low-grade astrocytomas and oligodendrogliomas and to improve their diagnosis and noninvasive assessment, because both types of tumors look very similar from the point of view of clinical and radiological data (as assessed by computed tomography and magnetic resonance imaging). METHODS: Before any aggressive treatment, 22 patients with primary low-grade gliomas (astrocytomas in 12 patients and oligodendrogliomas in 10) were investigated with positron emission tomography for both glucose metabolism (18F-fluorodeoxyglucose) and amino acid uptake (11C-L-methylmethionine). An original software that allows a full metabolic analysis of the tumor region of interest (defined from the T1-weighted magnetic resonance image) and compares tumor tissue uptake tracer concentrations with average healthy tissue values has been implemented for data processing. Heterogeneity of each individual tumor has been taken into account and was expressed in histograms, which provided data about the mean and also extreme and intermediate values of tracer concentrations and the way these values are distributed among the full tumor mass. RESULTS: It has been shown that both tumor types exhibit a glucose hypometabolism (slightly more pronounced with astrocytomas), whereas they strongly differ in methionine uptake, which is high in all oligodendrogliomas and either decreased, normal, or moderately increased in astrocytomas. This latter metabolic difference between both tumor populations may be partially explained by their different cell densities. CONCLUSION: This study suggests that despite similar radiological and clinical presentations, these two kinds of low-grade gliomas are metabolically different and could therefore have specific responses to different therapies. Moreover, their in vivo metabolic follow-up with positron emission tomography should rely on different parameters, depending on their histological type; methionine uptake may be more relevant than glucose metabolism in the follow-up of oligodendrogliomas.
OBJECTIVE: The object of the present study was to identify metabolic differences between low-grade astrocytomas and oligodendrogliomas and to improve their diagnosis and noninvasive assessment, because both types of tumors look very similar from the point of view of clinical and radiological data (as assessed by computed tomography and magnetic resonance imaging). METHODS: Before any aggressive treatment, 22 patients with primary low-grade gliomas (astrocytomas in 12 patients and oligodendrogliomas in 10) were investigated with positron emission tomography for both glucose metabolism (18F-fluorodeoxyglucose) and amino acid uptake (11C-L-methylmethionine). An original software that allows a full metabolic analysis of the tumor region of interest (defined from the T1-weighted magnetic resonance image) and compares tumor tissue uptake tracer concentrations with average healthy tissue values has been implemented for data processing. Heterogeneity of each individual tumor has been taken into account and was expressed in histograms, which provided data about the mean and also extreme and intermediate values of tracer concentrations and the way these values are distributed among the full tumor mass. RESULTS: It has been shown that both tumor types exhibit a glucose hypometabolism (slightly more pronounced with astrocytomas), whereas they strongly differ in methionine uptake, which is high in all oligodendrogliomas and either decreased, normal, or moderately increased in astrocytomas. This latter metabolic difference between both tumor populations may be partially explained by their different cell densities. CONCLUSION: This study suggests that despite similar radiological and clinical presentations, these two kinds of low-grade gliomas are metabolically different and could therefore have specific responses to different therapies. Moreover, their in vivo metabolic follow-up with positron emission tomography should rely on different parameters, depending on their histological type; methionine uptake may be more relevant than glucose metabolism in the follow-up of oligodendrogliomas.
Authors: D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger Journal: Radiologe Date: 2004-07 Impact factor: 0.635
Authors: D S Rosenberg; G Demarquay; A Jouvet; D Le Bars; N Streichenberger; M Sindou; N Kopp; F Mauguière; P Ryvlin Journal: J Neurol Neurosurg Psychiatry Date: 2005-12 Impact factor: 10.154
Authors: Michael Roslin; Roger Henriksson; Per Bergström; Urban Ungerstedt; A Tommy Bergenheim Journal: J Neurooncol Date: 2003-01 Impact factor: 4.130
Authors: Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2012-12-12 Impact factor: 9.236
Authors: F Giammarile; L E Cinotti; A Jouvet; J M Ramackers; G Saint Pierre; P Thiesse; E Jouanneau; J Guyotat; I Pelissou-Guyotat; A Setiey; J Honnorat; D Le Bars; D Frappaz Journal: J Neurooncol Date: 2004-07 Impact factor: 4.130
Authors: T Kato; J Shinoda; N Nakayama; K Miwa; A Okumura; H Yano; S Yoshimura; T Maruyama; Y Muragaki; T Iwama Journal: AJNR Am J Neuroradiol Date: 2008-04-03 Impact factor: 3.825
Authors: T Kato; J Shinoda; N Oka; K Miwa; N Nakayama; H Yano; T Maruyama; Y Muragaki; T Iwama Journal: AJNR Am J Neuroradiol Date: 2008-08-07 Impact factor: 3.825